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Aim: Astragalus membranaceus is a Chinese medicinal herb and has been shown to improve
hapten-induced experimental colitis. One of its major components is polysaccharides. We investigated
the effect of Astragalus polysaccharides (APS) on expression of TNF-a, IL-1b and NFATc4 in a rat model
of experimental colitis.
Methods: The experimental colitis model was induced by TNBS. Forty ﬁve rats were divided into ﬁve
groups (n = 9): Normal control group, receiving ethanol vehicle with no TNBS during induction and IP
saline injection during treatment; TNBS colitis model group (TNBS + IP saline), receiving only IP saline
vehicle treatment; APS low dose group (TNBS + L-APS), receiving APS 100 mg/kg; APS high dose group
(TNBS + H-APS), receiving APS 200 mg/kg; and positive control group (TNBS + Dexm), receiving dexa-
methasone 0.3 mg/kg. The clinical features, macroscopic and microscopic scores were assessed. The
expressions of TNF-a, IL-1b and NFATc4 were measured by real-time PCR and ELISA assays.
Results: Compared to normal control rats, TNBS + IP saline had signiﬁcant weight loss, increased macro-
scopic and microscopic scores, higher disease activity index (DAI) up-regulation of TNF-a, IL-1b and
NFATc4 mRNA expression and up-regulation of TNF-a and IL-1b protein expression. Compared to
TNBS + IP saline, treatment with APS or dexamethasone signiﬁcantly reduced DAI, partially but signiﬁ-
cantly prevented TNBS colitis-induced weight loss and improved both macroscopic and microscopic
scores; high dose APS or dexamethasone signiﬁcantly down-regulated TNF-a and IL-1b expressions (both
mRNA and protein) and up-regulated NFATc4 mRNA and protein expression. The effect of high dose APS
and dexamethasone is comparable.
Conclusions: APS signiﬁcantly improved experimental TNBS-induced colitis in rats through regulation of
TNF-a, IL-1b and NFATc4 expression.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Inﬂammatory bowel disease (IBD), including Crohn’s disease
and ulcerative colitis, is a chronic idiopathic inﬂammatory disorder
that affects the gastrointestinal tract of children and adults. The
precise etiology of IBD remains unclear. The current hypothesis
states that complex interactions among various factors, including
genetic factors, the host immune system and environmental
factors, cause disruption of intestinal homeostasis, leading todysregulated inﬂammatory responses of the gut [1–3]. Basic and
translational research [4,5] has led to a better understanding of
the role of inﬂammatory mediators including cytokines in the gut
of patients with IBD. Cytokines carry signals between immune,
epithelial and mesenchymal cells and play a pivotal role in the
development of IBD. The inﬂammatory cytokines are the most
logical targets for IBD treatment. Among various cytokines, tumor
necrosis factor-a (TNF-a) is the cytokine that has been widely
studied. Currently, several TNF-a blockers (inﬂiximab,
adalimumab and certolizumab) have been approved for IBD ther-
apy in clinical practice [6]. The choice of treatment depends on
severity, localization and the course of the disease [7]. Although
these available agents have shown clinical beneﬁts to some degree,
they are not entirely effective and have multiple adverse effects.
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often leads to drug refractoriness or intolerance [8]. Therefore, it
is necessary to develop novel therapeutic approaches.
Various natural products have been shown to safely suppress
the pro-inﬂammatory pathway and control IBD. In vivo and/or
in vitro studies suggest [9–11] that the anti-IBD effects exhibited
by natural products are mainly caused by their ability to modulate
cytokine production such as TNFa, IL-1b, IL-6 and IL-17. Traditional
Chinese medicine (TCM) has received great interest in recent years.
Astragalus membranaceus is a Chinese herb and has been used in
China for more than 2,000 years to strengthen human immunity.
Ko et al. [12] demonstrated that root extract of Astragalus membra-
naceus administered orally and locally can protect rats against
hapten-induced colitis through attenuation of TNF-a and IL-1b
and up-regulation of IL-10. However, it is still unknown what
active component is mainly responsible for the effect of Astragalus
membranaceus on experimental colitis.
Astragalus membranaceus contains different active components,
including polysaccharides, ﬂavonoids, astragalosides I–VII (sapo-
nins), amino acids and trace elements [12–14]. Our previous
studies have demonstrated that Astragalus polysaccharides (APS)
has a potent effect on erythroid lineage differentiation and
increases expression of NFATc4 mRNA by gene expression proﬁle
analysis in K562 cells [15]. NFATc4 is a key modulator of intestinal
cell proliferation and differentiation. It is one of the crucial tran-
scription factors that tightly control pro-inﬂammatory cytokine
expression for adaptive immunity in T and B lymphocytes [16].
We hypothesize that APS is the main active component of Astraga-
lus membranaceus that would improve experimental colitis. We
therefore investigated the effect of APS on expression of TNF-a,
IL-1b and NFATc4 in a rat model of experimental colitis.2. Methods
2.1. Animals
45 pathogen- free male Wistar rats, weighting 180–220 g, were
obtained from the animal facility of Nanfang Medical University
(Guangzhou, China). All animals were allowed free access to tap
water and standard chow diet. They were adapted to laboratory
conditions for 7 days, with 12 h day/night cycles at 23 C and 60%
humidity. All animal protocols were reviewed and approved by
Guangzhou Women and Children’s Medical Center Institutional
Review Committee on Laboratory Animal Care and all animals
were handled in accordance with institutional guidelines.
2.2. Animal model of colitis
Colitis was induced in the rats by rectal administration of Trini-
trobenzene sulfonic acid (TNBS) (Sigma) into the colons in a dose of
150 mg/kg, dissolved in 50% solution of ethanol as described by
others [17]. Brieﬂy, the animals were anaesthetized with 10% Chlo-
ral hydrate (300 mg/kg), and 3 ml/kg of TNBS – ethanol solution
(50 mg/ml) was administered into the colon at the depth of 8 cm
from the rectum with the use of a soft polyethylene catheter. The
rats were positioned in the Trendelenburg position for one minute
in order to avoid loss of TNBS solution via the rectum. Normal con-
trol animals received rectal administration of 50% ethanol solution
at 3 ml/kg without TNBS during induction.
2.3. Experimental protocol and sample preparation
72 h after induction of colitis, animals were treated daily by
intraperitoneal injection (IP) for 7 days. Animals in the normal
control group (Normal control) received ethanol vehicle with noTNBS during induction and received IP saline injection during
treatment. TNBS-induced colitis animals were randomly divided
into 4 treatment groups: TNBS colitis control group, receiving only
saline vehicle treatment (TNBS + IP saline); APS low dose treat-
ment group, receiving APS 100 mg/kg (TNBS + L-APS); APS high
dose treatment group, receiving APS 200 mg/kg (TNBS + H-APS);
and dexamethasone treatment group, receiving dexamethasone
0.3 mg/kg (TNBS + Dexm).
Animals were then allowed to recover and observed daily
throughout the duration of the study. Clinical symptoms, including
the amount of food consumed, consistency and frequency of stools
and the change of body weight were monitored until tissue
harvest.
24 h after the last treatment, all animals were sacriﬁced after
being deeply anesthetized with ether. The distal 8 cm of colon from
rectum was removed, dissected along the longitudinal mesentery,
rinsed with isotonic saline and assessed for extent of colonic
mucosa injuries. Multiple tissue specimens about 0.3 cm  0.5 cm
were prepared for microscopic examination, real-time PCR and
ELISA assays.
2.4. Disease activity index
Disease activity index (DAI) was based on weight loss, stool
consistency and blood in stools. Brieﬂy, score was assigned for each
item to calculate DAI as follows: (i) Percentage of weight loss: 0,
none; 1, 1–5%; 2, 6–10%; 3, 11–15%; 4, >15%. (ii) Stool consistency:
0, normal; 2, loose stool; 4, diarrhea. (iii) Blood in stools: 0, hemoc-
cult (); 1, hemoccult (±); 2, hemoccult (+); 3, hemoccult (++); 4,
gross bleeding. All animals were monitored daily for the duration
of the study to assess DAI changes in response to treatment.
2.5. Macroscopic and microscopic assessment
The removed colon was excised free of adherent adipose tissue,
rinsed with ice-cold saline and dissected longitudinally. It was
examined visually immediately and damage was scored on a scale
of 0–5 by the pathologists who were blinded to the group, as pre-
viously described by others [18]. Brieﬂy, scoring of macroscopic
colon damage was as follows: 0, no colonic damage; 1, hyperaemia
and no ulcer; 2, linear ulcer and no colonic wall thickening; 3, lin-
ear ulcer and colonic wall thickening in one area; 4, colonic ulcer at
multiple areas; and 5, major ulcer and perforation.
The samples of colonic tissue were routinely ﬁxed and stained
for microscopic examination. Four samples for each group were
selected randomly and their parafﬁn blocks were prepared. Four
parafﬁn blocks were investigated. The colonic pathological changes
were observed and evaluated by two trained independent
researchers using a modiﬁed histopathological score formula
[19]: (i) inﬁltration of acute inﬂammatory cells: 0 none, 1 mild, 2
severe; (ii) inﬁltration of chronic inﬂammatory cells: 0 none, 1
mild, 2 severe; (iii) ﬁbrin deposition: 0 negative, 1 positive; (iv)
submucosal oedema: 0 none, 1 focal, 2 diffuse; (v) necrosis of epi-
thelial cells: 0 none, 1 focal, 2 diffuse; and (vi) mucosal ulcer: 0
negative, 1 positive.
2.6. Real-time PCR analysis
Total RNA was isolated from colonic tissue using the TRIzol
reagent. Reverse transcription of the isolated RNA was performed
in a solution containing 4 lg of total RNA, 1 lg of Oligo (dT),
10 lL of 5 buffer, 2.5 lL of 10 mM dNTPs, and 400 U of MMLV
reverse transcriptase. The ﬁnal reaction volume was 50 lL. The
reverse transcription was performed at 42 C for 1 h. Real-time
PCR was conducted according to the manual of SYBR ExScript™
RTPCR kit using a Stratagene Mx3000P QPCR system. The primers
Table 1
Primer sequences, annealing temperature and product size with real-time PCR.
Target
gene
Primer sequences(50->30) Annealing
temperature
(C)
Product
size (bp)
b-Actin (rat) F: AGAGGGAAATCGTGCGTGAC 60 195
R: CCATACCCAGGAAGGAAGGCT
TNF-a (rat) F: AAATGGGCTCCCTCTCATCAGTTC 60 111
R: TCTGCTTGGTGGTTTGCTACGAC
IL-1b (rat) F: TGAGGCTGACAGACCCCAAAAGAT 60 181
R: GCTCCACGGGCAAGACATAGGTAG
NFATc4 (rat) F: ACAGAAGAGGGGGCGTCTCAGA 59 299
R: ACCAATAGGGGCAGCACCATAA
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tional, Palo Alto, CA, USA). All primer sequences, thermal cycling
conditions, and product sizes are shown in Table 1.Gene expression
levels were recorded as threshold cycle (Ct) values. Each sample
was ampliﬁed twice. A melting curve analysis was performed on
each sample to ensure single ampliﬁcation. The amount of target
genes was standardized via comparison with the amount of b-actin
mRNA.
The relative fold increase of gene expression was calculated by
setting 244Ct value of normal control as 1.2.7. ELISA assays
To quantify colonic tissue cytokines, 50 mg of colonic tissue was
extracted using 500 ll of 5 M guanidine HCl and 50 mM Tris–HCl
(pH 8.0) with a protease inhibitor. The extracts were centrifuged
at 15, 000 g for 30 min at 4 C to remove insoluble materials. The
supernatant fractions were analyzed by ELISA kit (ADL, San Diego,
USA) according to instructions after total protein determination. To
quantify TNF-a, IL-1b and NFATc4 protein in colon tissue, the 1:20
dilutions of the supernatants of colonic tissue homogenates were
added into 96-well microplates. These microplates were coated
with antibodies speciﬁc for rat. After the enzyme-substrate reac-
tion, sample absorbances were measured at 450 nm with a micro-
plate reader. Standard curves were prepared like the samples using
diluted standard solutions. These curves were used to provide
comparisons for the calculations of rat TNF-a, IL-1b and NFATc4
in the samples. All standards and samples were run in duplicate.2.8. Statistical analysis
All parameters were expressed as mean ± SE. Statistical analysis
was performed using one-way ANOVA followed by the Duncan’sTable 2
Effects of Astragalus polysaccharides (APS) on body weight change, disease activity index
Groups Body weight changed from baseline (%) DAI (Max
Normal control 2.78 ± 1.30 0.00 ± 0.0
TNBS + IP saline 8.19 ± 0.70# 5.00 ± 0.8
TNBS + L-APS 4.67 ± 0.63** 2.33 ± 0.8
TNBS + H-APS 1.74 ± 0.72** 1.67 ± 0.5
TNBS + Dexm 1.12 ± 0.49** 1.44 ± 0.7
Colitis in rats was induced by rectal administration of TNBS. Animals in normal control g
injection during treatment; TNBS colitis control group: only IP saline vehicle treatment (T
high dose treatment group: APS 200 mg/kg (TNBS + H-APS); and dexamethasone treatme
as mean ± SE (n = 9). Max: maximum score.
*P < 0.01 vs. TNBS + IP saline.
# P < 0.001 vs. normal group.
** P < 0.001 vs. TNBS + IP saline.multiple range test (SPSS version 10.0). A P-value of less than
0.05 was considered signiﬁcantly different.
3. Results
3.1. Clinical features
After intracolonic instillation of TNBS, stool frequency was
increased and stool characteristics were loose or watery with some
mucus and/or blood. None of the rats died during the experimental
period.
As shown in Table 2, compared to normal control animals,
TNBS + IP saline rats had signiﬁcant weight loss at the end of
experiment from baseline (p < 0.001). Treatments with low dose
APS, high dose APS or dexamethasone partially but signiﬁcantly
prevented TNBS colitis-induced weight loss (F = 226.3, p < 0.001).
There was no signiﬁcant differences in body weight changes in ani-
mals between TNBS + H-APS and TNBS + Dexm groups (P = 0.115).
Disease activity index was signiﬁcantly higher in TNBS+IP saline
animals than normal controls (p < 0.001). Treatments with low
dose APS, high dose APS or dexamethasone signiﬁcantly reduced
disease activity index (F = 66.634, p < 0.001). There was no signiﬁ-
cant differences in disease activity index in animals between
TNBS + H-APS groups and TNBS + Dexm groups (P = 0.489).
3.2. Macroscopic and microscopic assessment
As shown in Table 2, macroscopic and microscopic scores were
signiﬁcantly higher in TNBS + IP saline animals than normal con-
trols (p < 0.001). Compared to TNBS + IP saline animals, treatment
with low dose APS, high dose APS or dexamethasone signiﬁcantly
deceased both macroscopic and microscopic scores (F = 52.029,
P = 0.000; F = 78.289, P = 0.000, respectively). The improvement of
macroscopic and microscopic scores with H-APS were comparable
to those with dexamethasone (P = 0.861 and P = 0.184,
respectively).
In TNBS + IP saline animals, histological exam showed edema,
mucosal necrosis, and loss of the epithelium. There were diffuse
polymorphonuclear leukocyte inﬁltrations in lamina propria and
muscularis mucosa (Fig. 1B). There were mild edema and moderate
inﬂammatory cell inﬁltration in TNBS+L-APS rats (Fig. 1C). In high
dose APS and dexamethasone groups, colonic structures were nor-
mal and there was marked reduction of inﬂammatory inﬁltrates,
mild edema limited mainly to the lamina propria and minimal
ulceration (Fig. 1D and E).
3.3. TNF-a, IL-1b and NFATc4 mRNA expression by real-time PCR
Real-time PCR detections were performed to evaluate the level
of TNF-a, IL-1b and NFATc4 mRNA expression. Compared to(DAI), macroscopic and microscopic scores in TNBS-induced colitis in rats.
12) Macroscopic score (Max 5) Microscopic score (Max 10)
0 0.00 ± 0.00 0.00 ± 0.00
7# 3.67 ± 0.71 # 5.11 ± 0.78#
7** 2.22 ± 0.83** 3.89 ± 0.78**
0** 0.78 ± 0.67** 1.44 ± 0.88**
3** 0.56 ± 0.53** 0.78 ± 0.83**
roup (Normal control): ethanol vehicle with no TNBS during induction and IP saline
NBS + IP saline); APS low dose treatment group: APS 100 mg/kg (TNBS + L-APS); APS
nt group, receiving dexamethasone 0.3 mg/kg (TNBS + Dexm). Results are expressed
Fig. 1. Histopathological appearance of colonic tissue in rats. (A) Normal colonic mucosa in normal control rats. (B) Edema, mucosal necrosis, and loss of the epithelium in
TNBS-induced colitis rats. (C) Mild edema and moderate inﬂammatory cell inﬁltration in lower dose (100 mg/kg) APS -treated rats. (D) Colonic mucosa of high dose (200 mg/
kg) APS-treated rats. (E) Colonic mucosa of 0.3 mg/kg dexamethasone-treated rats. In both high dose APS and dexamethasone treatment group, the colon structure was
normal and there was marked reduction of the inﬂammatory inﬁltrate, mild edema limited mainly to the lamina propria and minimal ulceration. (H&E 400).
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all signiﬁcantly up-regulated in TNBS colitis rats (Fig. 2A–C).
Treatments with high dose APS or dexamethasone signiﬁcantly
down-regulated TNF-a and IL-1b mRNA expressions but up-regu-
lated NFATc4 mRNA expression in comparison to TNBS colitis
group. APS at low dose signiﬁcantly down-regulated IL-1b mRNA,
up-regulated NFATc4 mRNA and only slightly down-regulated
TNF-a mRNA (not reaching statistical signiﬁcance). The effects of
APS on TNF-a, IL-1b and NFATc4 mRNA expression appear dose-
dependent.3.4. TNF-a, IL-1b and NFATc4 protein expression by ELISA
ELISA assays were performed to evaluate the level of TNF-a, IL-
1b and NFATc4 protein expression. Compared to normal controls,
TNF-a and IL-1b protein expressions were signiﬁcantly up-
regulated in TNBS colitis rats (Fig. 2D–F). Treatments with high
dose APS or dexamethasone signiﬁcantly down-regulated TNF-a
and IL-1b protein expressions in comparison to the TNBS colitis
group. APS at low dose signiﬁcantly down-regulated IL-1b protein
but did not have a signiﬁcant effect on TNF-a protein expression.
NFATc4 protein expression did not differ between normal con-
trol and the TNBS colitis group. However, compared to TNBS colitis
or normal control groups, high dose APS or dexamethasone, but not
low dose APS, signiﬁcantly up-regulated NFATc4 protein expres-
sion (2F).4. Discussion
The search for active compounds in natural products used in
traditional medicine has attracted great interest [9,20–22]. In Tra-
ditional Chinese Medicine, Astragalus membranaceus is a major
component in a prescription to treat chronic phlegmatic disorders
and general gastrointestinal disturbances including stomach ulcer,
chronic diarrhea and intestinal inﬂammation. Recent studies sug-
gested that Astragalus membranaceus have pharmacological effects
on the activation of B cells and macrophages, regulation of both
humoral and cellular immune responses, cardiovascular protection
and prevention of inﬂammation and cancer [23–25]. Astragalus
membranaceus has pharmacological effects on regulating epithelial
cell proliferation [26], formation of intestinal epithelial cellconnections and cell differentiation, alleviating intestinal patho-
logical lesions. Astragalus polysaccharides (APS) is the main active
ingredient in Astragalus membranaceus. The present study demon-
strated that APS signiﬁcantly improved TNBS-induced colitis with
improvement of diarrhea and both macroscopic and microscopic
scores, in a dose-dependent manner. The protective effect of high
dose APS is comparable to that of dexamethasone.
Cytokines are key signaling molecules of the intestinal immune
system, which play an important role in IBD. In vivo and/or in vitro
studies indicate that the levels of proinﬂammatory cytokines,
including interleukin IL-1b, IL-18, IL-6, TNF-a, and TL1A (tumor
necrosis factor-like ligand) are increased in active IBD and corre-
late with the severity of inﬂammation [27,28]. TNF-a is one of
the most important pro-inﬂammatory cytokines that directly inﬂu-
ence intestinal epithelial tissue and IL-1b is also a key mediator of
IBD progression [29]. Excessive TNF-a expression results in dam-
age to the epithelial barrier, initiation of apoptosis in epithelial
cells, and initiation of chemokine secretion by colonic epithelial
cells. A persistent increase in TNF-a in colonic mucosa may con-
tribute to the epithelial barrier defects associated with intestinal
inﬂammation seen in IBD [30]. In our animal model of TNBS-
induced experimental colitis, TNF-a and IL-1b expressions were
signiﬁcantly up-regulated, further conﬁrming the critical role of
these pro-inﬂammatory cytokines in the pathogenesis of intestinal
inﬂammation.
Various natural products have been shown to suppress pro-
inﬂammatory pathways and control IBD. Studies indicate that
APS could suppress the production of TNF-a, IL-1b and IL-8
[31,32]. This study provided evidence that APS might protect rats
against TNBS-induced colitis through modulation of TNF-a and
IL-1b. The expression of TNF-a and IL-1b mRNA and protein were
down-regulated after treatment with high dose (200 mg/kg) APS
in TNBS-treated rats, which is consistent with results reported by
others [32].
The intestinal epithelial barrier is the frontline between genetic,
environmental, and immunological factors [33,34], and is main-
tained by normal intestinal ﬂora, epithelial-cell proliferation, cell-
matrix adhesion molecules, intact endoplasmic reticulum stress
response, and prompt epithelial restitution after injury [35,36].
The inﬂammatory response often results in continued epithelial
injury, which causes erosions, ulcerations, and a decrease in the
production of a-defensin [37,38]. Studies have shown that nuclear
Fig. 2. Effects of Astragalus polysaccharides (APS) on mRNA (A–C) and protein (D–F) expression of TNF-a, IL-1b and NFATc4 in colonic mucosa of rats. Colitis in rats was
induced by rectal administration of TNBS. Animals in normal control group (Normal control): ethanol vehicle with no TNBS during induction and IP saline injection during
treatment; TNBS colitis control group: only IP saline vehicle treatment (TNBS + IP saline); APS low dose treatment group: APS 100 mg/kg (TNBS + L-APS); APS high dose
treatment group: APS 200 mg/kg (TNBS + H-APS); and dexamethasone treatment group: dexamethasone 0.3 mg/kg (TNBS + Dexm). Data are presented as mean ± SD.
##P < 0.01 vs. Normal group; *P < 0.05, **P < 0.01 vs. TNBS + IP saline.
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transcription factors which involve in the regulation of cell differ-
entiation and development in a number of cell types [15,39]. NFATs
are crucial transcription factors that tightly control proinﬂamma-
tory cytokine expression, including TNF-a and IL-1b, for adaptive
immunity in T and B lymphocytes and NFATc3 and c4 is required
for Toll-like receptor-initiated innate inﬂammatory immune
response in bone marrow derived macrophages [16]. However,
little is known about the role of NFATs in IBD.
In this study, we attempted to determine whether NFATc4 is
involved in TNBS-induced colitis. NFATc4 mRNA and protein were
detected in normal colonic mucosa, but only NFATc4 mRNA was
up-regulated after induction of colitis, indicating NFATc4 may be
involved in pathogenesis of colitis through regulation of down-
stream gene expression at the transcription level. Surprisingly,
after APS treatment, while TNF-a and IL-1b expression was
down-regulated, NFATc4 mRNA and protein expression was
further up-regulated, not down-regulated towards that in normal
controls as one would expect. This may suggest a protective
mechanism of NFATc4 with APS treatment of TNBS-induced colitis.
Wang et al [40] reported that NFATc4 is a key modulator ofintestinal cell proliferation and differentiation. We speculate that
up-regulated expression of NFATc4 by APS may represent a
damage repairing process, leading to improvement of colitis. Fur-
ther studies are needed to clarify the exact role of NFATs in colitis
and how it interacts with TNF-a and IL-1b.
In conclusion, this study provides evidence that APS signiﬁcantly
improves TNBS-induced experimental colitis, through regulation of
TNF-a, IL-1b and NFATc4 expression. It provides important new
insight that may contribute to further development of APS as a
novel therapeutic agent for inﬂammatory bowel disease.Acknowledgement
The present study was supported by grants from Administra-
tion of Traditional Chinese Medicine of Guangdong Province
Foundation (No. 2009030).References
[1] Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inﬂammatory
bowel disease. Nature 2011;474:298–306.
86 M. Yang et al. / Cytokine 70 (2014) 81–86[2] Abraham C, Cho JH. Inﬂammatory bowel disease. New England J Med
2009;361:2066–78.
[3] Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inﬂammatory bowel
disease. Nature 2007;448:427–34.
[4] Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inﬂammatory
pathways of importance for management of inﬂammatory bowel disease.
World J Gastroenterol: WJG 2014;20:64–77.
[5] Mustain WC, Starr ME, Valentino JD, Cohen DA, Okamura D, Wang C, et al.
Inﬂammatory cytokine gene expression in mesenteric adipose tissue during
acute experimental colitis. PLoS ONE 2013;8:e83693.
[6] Peake ST, Bernardo D, Mann ER, Al-Hassi HO, Knight SC, Hart AL. Mechanisms
of action of anti-tumor necrosis factor alpha agents in Crohn’s disease.
Inﬂamm Bowel Dis 2013;19:1546–55.
[7] Lim WC, Hanauer SB. Controversies with aminosalicylates in inﬂammatory
bowel disease. Rev Gastroenterol Dis 2004;4:104–17.
[8] Biasi F, Leonarduzzi G, Oteiza PI, Poli G. Inﬂammatory bowel disease:
mechanisms, redox considerations, and therapeutic targets. Antioxid Redox
Signal 2013;19:1711–47.
[9] Debnath T, Kim da H, Lim BO. Natural products as a source of anti-
inﬂammatory agents associated with inﬂammatory bowel disease. Molecules
2013;18:7253–70.
[10] Algieri F, Rodriguez-Nogales A, Garrido-Mesa N, Zorrilla P, Burkard N, Pischel I,
et al. Intestinal anti-inﬂammatory activity of the Serpylli herba extract in
experimental models of rodent colitis. J Crohn’s Colitis 2014.
[11] Hur SJ, Kang SH, Jung HS, Kim SC, Jeon HS, Kim IH, et al. Review of natural
products actions on cytokines in inﬂammatory bowel disease. Nutr Res
2012;32:801–16.
[12] Ko JK, Chik CW. The protective action of radix Astragalus membranaceus against
hapten-induced colitis through modulation of cytokines. Cytokine
2009;47:85–90.
[13] Mu LX, Zhu L, Zhao AH, Zhou MM, Jia W. Study on extraction and puriﬁcation
of polysaccharides from Astragalus membranaceus. Zhong yao
cai = Zhongyaocai = J Chinese Med Mater 2009;32:1741–5.
[14] Ma XQ, Shi Q, Duan JA, Dong TT, Tsim KW. Chemical analysis of Radix Astragali
(Huangqi) in China: a comparison with its adulterants and seasonal variations.
J Agric Food Chem 2002;50:4861–6.
[15] Yang M, Qian XH, Zhao DH, Fu SZ. Effects of Astragalus polysaccharide on the
erythroid lineage and microarray analysis in K562 cells. J Ethnopharmacol
2010;127:242–50.
[16] Minematsu H, Shin MJ, Celil Aydemir AB, Kim KO, Nizami SA, Chung GJ, et al.
Nuclear presence of nuclear factor of activated T cells (NFAT) c3 and c4 is
required for Toll-like receptor-activated innate inﬂammatory response of
monocytes/macrophages. Cellular Signalling 2011;23:1785–93.
[17] Zheng L, Gao ZQ, Wang SX. A chronic ulcerative colitis model in rats. World J
Gastroenterol: WJG 2000;6:150–2.
[18] Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL.
Hapten-induced model of chronic inﬂammation and ulceration in the rat
colon. Gastroenterology 1989;96:795–803.
[19] Millar AD, Rampton DS, Chander CL, Claxson AW, Blades S, Coumbe A, et al.
Evaluating the antioxidant potential of new treatments for inﬂammatory
bowel disease using a rat model of colitis. Gut 1996;39:407–15.
[20] Ke X, Chen J, Zhang X, Fang W, Yang C, Peng J, et al. Qing Hua Chang Yin
attenuates lipopolysaccharide-induced inﬂammatory response in human
intestinal cells by inhibiting NF-kappaB activation. Experim Therapeut Med
2013;6:189–93.
[21] Bensoussan M, Jovenin N, Garcia B, Vandromme L, Jolly D, Bouche O, et al.
Complementary and alternative medicine use by patients with inﬂammatory
bowel disease: results from a postal survey. Gastroenterol Clin Biol
2006;30:14–23.[22] Langmead L, Rampton DS. Review article: complementary and alternative
therapies for inﬂammatory bowel disease. Aliment Pharmacol Ther
2006;23:341–9.
[23] Shao BM, Xu W, Dai H, Tu P, Li Z, Gao XM. A study on the immune receptors for
polysaccharides from the roots of Astragalus membranaceus, a Chinese
medicinal herb. Biochem Biophys Res Commun 2004;320:1103–11.
[24] Wang GL, Chen CB, Gao JM, Ni H, Wang TS, Chen L. Investigation on the
molecular mechanisms of anti-hepatocarcinoma herbs of traditional Chinese
medicine by cell cycle microarray. Zhongguo Zhong yao za zhi = Zhongguo
zhongyao zazhi =. China J Chinese Materia Medica 2005;30:50–4.
[25] Tian QE, Li HD, Yan M, Cai HL, Tan QY, Zhang WY. Astragalus polysaccharides
can regulate cytokine and P-glycoprotein expression in H22 tumor-bearing
mice. World J Gastroenterol: WJG 2012;18:7079–86.
[26] Zhang ZL, Chen WW. Effect of Astragalus injection in promoting IEC-6 cell
differentiation through activating ornithine decarboxylase. Zhongguo Zhong xi
yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese Journal of Integrated
Traditional and Western Medicine/Zhongguo Zhong xi yi jie he xue hui,
Zhongguo Zhong yi yan jiu yuan zhu ban, vol. 22; 2002, pp. 439–43.
[27] Kim JM. Inﬂammatory bowel diseases and inﬂammasome. Korean J
Gastroenterology = Taehan Sohwagi Hakhoe chi 2011;58:300–10.
[28] Strober W, Fuss IJ. Proinﬂammatory cytokines in the pathogenesis of
inﬂammatory bowel diseases. Gastroenterology 2011;140:1756–67.
[29] Cho EJ, Shin JS, Noh YS, Cho YW, Hong SJ, Park JH, et al. Anti-inﬂammatory
effects of methanol extract of Patrinia scabiosaefolia in mice with ulcerative
colitis. J Ethnopharmacol 2011;136:428–35.
[30] Vivinus-Nebot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R,
et al. Functional bowel symptoms in quiescent inﬂammatory bowel diseases:
role of epithelial barrier disruption and low-grade inﬂammation. Gut 2013.
[31] Yuan Y, Sun M, Li KS. Astragalus mongholicus polysaccharide inhibits
lipopolysaccharide-induced production of TNF-alpha and interleukin-8.
World J Gastroenterol: WJG 2009;15:3676–80.
[32] He X, Shu J, Xu L, Lu C, Lu A. Inhibitory effect of Astragalus polysaccharides on
lipopolysaccharide-induced TNF-a and IL-1beta production in THP-1 cells.
Molecules 2012;17:3155–64.
[33] Keita AV, Soderholm JD. Barrier dysfunction and bacterial uptake in the
follicle-associated epithelium of ileal Crohn’s disease. Ann New York Acad Sci
2012;1258:125–34.
[34] Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in
inﬂammatory bowel disease and potential therapeutics. J Physiol
2012;590:1035–44.
[35] Turner JR. Molecular basis of epithelial barrier regulation: from basic
mechanisms to clinical application. Am J Pathol 2006;169:1901–9.
[36] Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, et al. XBP1 links ER
stress to intestinal inﬂammation and confers genetic risk for human
inﬂammatory bowel disease. Cell 2008;134:743–56.
[37] Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL.
Reduced alpha-defensin expression is associated with inﬂammation and not
NOD2 mutation status in ileal Crohn’s disease. Gut 2008;57:903–10.
[38] Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, et al.
Reduced Paneth cell alpha-defensins in ileal Crohn’s disease. Proc Natl Acad Sci
USA 2005;102:18129–34.
[39] Johnstone LS, Graham SJ, Dziadek MA. STIM proteins: integrators of signalling
pathways in development, differentiation and disease. J Cell Mol Med
2010;14:1890–903.
[40] Wang Q, Zhou Y, Jackson LN, Johnson SM, Chow CW, Evers BM. Nuclear factor
of activated T cells (NFAT) signaling regulates PTEN expression and intestinal
cell differentiation. Mol Biol Cell 2011;22:412–20.
